Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FUFA is a combination chemotherapy regimen consisting of 5-fluorouracil (5-FU) and folinic acid (FA), also known as leucovorin. 5-fluorouracil is a fluoropyrimidine antimetabolite that acts as a thymidylate synthase (TS) inhibitor, disrupting DNA synthesis. Folinic acid is a reduced form of folic acid that stabilizes the binding of 5-FU to TS, thereby enhancing its cytotoxic activity. This specific regimen was evaluated by the University of Ulm in the FOGT5 Phase II clinical trial, which investigated the feasibility of stratifying patients with advanced or metastasized colorectal cancer based on their intratumoral thymidylate synthase mRNA expression levels to predict treatment response. FUFA represents a standard chemotherapy backbone that has been used for decades in colorectal cancer treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-fluorouracil + folinic acid (Ulm University).